|
2024 Conference Publication The cost-effectiveness of germline BRCA testing in prostate cancer followed by cascade testing of first-degree relatives of mutation carriersTeppala, S., Scuffham, P., Edmunds, K., Roberts, M., Fairbairn, D., Smith, D., Horvath, L. and Tuffaha, H. (2024). The cost-effectiveness of germline BRCA testing in prostate cancer followed by cascade testing of first-degree relatives of mutation carriers. ISPOR Europe 2024: Generating Evidence Toward Health and Well-Being, Barcelona, Spain, 17-20 November 2024. New York, United States: Elsevier. doi: 10.1016/j.jval.2024.10.610 |
|
2024 Conference Publication The cost-effectiveness of targeted germline BRCA testing in localised prostate cancer followed by cascade testing of first-degree relatives of mutation carriersTeppala, Srinivas, Scuffham, Paul, Edmunds, Kim, Roberts, Matthew, Fairbairn, David, Smith, David, Horvath, Lisa and Tuffaha, Haitham (2024). The cost-effectiveness of targeted germline BRCA testing in localised prostate cancer followed by cascade testing of first-degree relatives of mutation carriers. COSA's 51st Annual Scientific Meeting Bridging gaps, building progress, breaking down disparities, Gold Coast, QLD Australia, 13–15 November 2024. Richmond, VIC Australia: John Wiley & Sons. |
|
2024 Conference Publication The early oncological effect of extended pelvic lymph node dissection in men with at PSMA PET/CT N0M0 intermediate/high-risk prostate cancer - an international cohort studyVan Leeuwen, P.J., Berrens, A-C., Vis, A., Yaxley, J., Meijer, D., Siriwardana, A., Wit, E., Van Der Noort, V., Morton, A., Franklin, A., Yaxley, J., Wong, D., Goughlin, G., Gianduzzo, T., Kua, B., Emmett, L., Zuur, L., Van Der Poel, H. and Roberts, M. (2024). The early oncological effect of extended pelvic lymph node dissection in men with at PSMA PET/CT N0M0 intermediate/high-risk prostate cancer - an international cohort study. EAU24 - 39th Annual EAU Congress, Paris, France, 5-8 April 2024. Amsterdam, Netherlands: Elsevier. doi: 10.1016/s0302-2838(24)01002-9 |
|
2024 Conference Publication Combining MRI PI-RADS and PSMA-PET/CT PRIMARY score in a composite (P) score for more accurate diagnosis of clinically significant prostate cancerEmmett, L., Papa, N., Hope, T., Fendler, W., Calais, J., Burger, I., Eiber, M., Barbato, F., Moon, D., Xue, A., Franklin, A., Thompson, J., Rasiah, K., Frydenberg, M., Yaxley, J., Buteau, J., Liu, V., Nguyen, A., Hsiao, E., Stricker, P., Hofman, M., Kasivisvanathan, V., Roberts, M. and Murphy, D. (2024). Combining MRI PI-RADS and PSMA-PET/CT PRIMARY score in a composite (P) score for more accurate diagnosis of clinically significant prostate cancer. EAU24 - 39th Annual EAU Congress, Paris, France, 5-8 April 2024. Amsterdam, Netherlands: Elsevier. doi: 10.1016/s0302-2838(24)00417-2 |
|
2024 Conference Publication Early oncological outcomes following radical prostatectomy of patients with pelvic lymph node-positive prostate cancer at preoperative PSMA PET/CTZuur, L.G., de Bie, K., Vis, A.N., Van Der Poel, H.G., Donswijk, M.L., Oprea-Lager, D.E., Roberts, M. and Van Leeuwen, P.J. (2024). Early oncological outcomes following radical prostatectomy of patients with pelvic lymph node-positive prostate cancer at preoperative PSMA PET/CT. EAU24 - 39th Annual EAU Congress, Paris, France, 5-8 April 2024. Amsterdam, Netherlands: Elsevier. doi: 10.1016/s0302-2838(24)01187-4 |
|
2024 Conference Publication Development and external validation of a novel nomogram to predict the probability of pelvic lymph-node metastases in prostate cancer patients using magnetic resonance imaging and molecular imaging with prostate-specific membrane antigen positron emissionVis, A., Meijer, D., Roberts, M.J., Siriwardana, A.R., Morton, A., Yaxley, J.W., Samaratunga, H., Emmett, L., Van Der Ven, P.M., Heymans, M.W., Nieuwenhuijzen, J.A., Van Der Poel, H.G., Van Donswijk, M.L., Boellaard, T.N., Schoots, I.G., Stricker, P., Haynes, A-M., Oprea-Lager, D.E., Coughlin, G.D. and Van Leeuwen, P.J. (2024). Development and external validation of a novel nomogram to predict the probability of pelvic lymph-node metastases in prostate cancer patients using magnetic resonance imaging and molecular imaging with prostate-specific membrane antigen positron emission. EAU24 - 39th Annual EAU Congress, Paris, France, 5-8 April 2024. Amsterdam, Netherlands: Elsevier. doi: 10.1016/s0302-2838(24)00422-6 |
|
2023 Conference Publication Quality of health information in ChatGPT responses to common patient enquiries about recurrent UTI treatment and preventionCollin, Harry and Roberts, Matthew (2023). Quality of health information in ChatGPT responses to common patient enquiries about recurrent UTI treatment and prevention. Annual Scientific Meeting of the Singapore-Urological-Association (SUA), Singapore, 6-8 July 2023. Chichester, West Sussex, United Kingdom: Wiley-Blackwell. |
|
2023 Conference Publication Virtual healthcare delivery in urology - is AI the future for patient information on prostate cancer?Collin, Harry and Roberts, Matthew (2023). Virtual healthcare delivery in urology - is AI the future for patient information on prostate cancer?. Annual Scientific Meeting of the Singapore-Urological-Association (SUA), Singapore, 6-8 July 2023. Chichester, West Sussex, United Kingdom: Wiley-Blackwell. |
|
2023 Conference Publication Lu-PSMA Therapy - Practical considerations for urologistsCollin, Harry, Keogh, Kandice and Roberts, Matthew (2023). Lu-PSMA Therapy - Practical considerations for urologists. 2023 ANZUP Annual Scientific Meeting, Bouncing Back, Melbourne, VIC, Australia, 9-11 July 2023. Hoboken, NJ, United States: Wiley. |
|
2023 Conference Publication PRIMARY2 Trial Protocol: Phase III, multicentre, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancerButeau, James, Moon, Daniel, Fahey, Michael, Roberts, Matthew, Thompson, James, Murphy, Declan G., Papa, Nathan, Mitchell, Catherine, Kasivisvanathan, Veeru, Stricker, Phillip, O'Brien, Jonathan, Counter, William, Sharma, Gaurav, Agrawal, Shikha, Ho, Bao, Dilulio, Juliana, Lindeman, William, De Abreu, Lourenco Richard, Dhillon, Haryana M., Hofman, Michael S. and Emmett, Louise (2023). PRIMARY2 Trial Protocol: Phase III, multicentre, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer. 2023 ANZUP Annual Scientific Meeting, Bouncing Back, Melbourne, VIC, Australia, 9-11 July 2023. Hoboken, NJ, United States: Wiley. |
|
2023 Conference Publication Can artificial intelligence devise surveillance regimens for testicular cancer?Collin, Harry, Keogh, Kandice and Roberts, Matthew (2023). Can artificial intelligence devise surveillance regimens for testicular cancer?. 2023 ANZUP Annual Scientific Meeting, Bouncing Back, Melbourne, VIC, Australia, 9-11 July 2023. Hoboken, NJ, United States: Wiley. |
|
2023 Conference Publication Dr Bot - Does AI provide quality information to prostate cancer patients?Collin, Harry, Keogh, Kandice and Roberts, Matthew (2023). Dr Bot - Does AI provide quality information to prostate cancer patients?. 2023 ANZUP Annual Scientific Meeting, Bouncing Back, Melbourne, VIC, Australia, 9-11 July 2023. Hoboken, NJ, United States: Wiley. |
|
2023 Conference Publication Initial diagnostic accuracy of FDG-PET compared to PSMA-PET for newly diagnosed high risk prostate cancer prior to treatment: FIND TrialRoberts, Matthew, Roberts, Natasha, Harley, Simon, Cullen, Karla, Pelecanos, Anita, Vela, Ian, Yaxley, John, Kuchel, Anna, Dhiantravan, Nattakorn, Thomas, Paul and Pattison, David (2023). Initial diagnostic accuracy of FDG-PET compared to PSMA-PET for newly diagnosed high risk prostate cancer prior to treatment: FIND Trial. 2023 ANZUP Annual Scientific Meeting, Bouncing Back, Melbourne, VIC, Australia, 9-11 July 2023. Hoboken, NJ, United States: Wiley. |
|
2023 Conference Publication Adding mitomycin (MM) to bacillus Calmette-Guerin (BCG) as adjuvant intravesical therapy for high-risk, non-muscle-invasive urothelial bladder cancer (NMIBC)Hayne, Dickon, Stockler, Martin R., Martin, Andrew James, McCombie, Steve P., Zebic, Danka Sinikovic, Bastick, Patricia A., Beardsley, Emma Kate, Frydenberg, Mark, Green, William, Grummet, Jeremy, Hawks, Cynthia, Ischia, Joseph, Mitterdorfer, Andrew, Patel, Manish, Roberts, Matthew, Sengupta, Shomik, Srivastav, Ratnesh Kumar, Redfern, Andrew David and Davis, Ian D. (2023). Adding mitomycin (MM) to bacillus Calmette-Guerin (BCG) as adjuvant intravesical therapy for high-risk, non-muscle-invasive urothelial bladder cancer (NMIBC). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL USA, 2-6 June 2023. Philadelphia, PA USA: Lippincott Williams & Wilkins. |
|
2023 Conference Publication PRIMARY2: A phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancerButeau, James Patrick, Moon, Daniel, Fahey, Michael T., Roberts, Matthew, Thompson, James, Murphy, Declan G., Papa, Nathan, Mitchell, Catherine, Kasivisvanathan, Veeru, Stricker, Phillip, O'Brien, Jonathan, Counter, William, Sharma, Gaurav, Agrawal, Shikha, Ho, Bao, Yeung, Theresa, Lourenco, Richard De Abreu, Dhillon, Haryana M., Hofman, Michael S. and Emmett, Louise (2023). PRIMARY2: A phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer. Genitourinary Cancers Symposium, Electr Network, 16-18 February 2023. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2023.41.6_suppl.TPS397 |
|
2023 Conference Publication PRIMARY2: A phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancerButeau, James Patrick, Moon, Daniel, Fahey, Michael T., Roberts, Matthew, Thompson, James, Murphy, Declan G., Papa, Nathan, Mitchell, Catherine, Kasivisvanathan, Veeru, Stricker, Phillip, O'Brien, Jonathan, Counter, William, Sharma, Gaurav, Agrawal, Shikha, Ho, Bao, Yeung, Theresa, De Abreu Lourenço, Richard, Dhillon, Haryana M., Hofman, Michael S and Emmett, Louise (2023). PRIMARY2: A phase III, multi-centre, randomised controlled trial investigating the additive diagnostic value of [68Ga]Ga-PSMA-11 PET/CT in men with negative/equivocal MRI in the diagnosis of clinically significant prostate cancer. 2023 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 16-18 February 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.6_suppl.tps397 |
|
2023 Conference Publication Baseline PSMA PET-CT is prognostic for treatment failure in men with intermediate-to-high risk prostate cancer: 54 months follow-up of the proPSMA randomised trialKasivisvanathan, V., Murphy, D.G., Link, E., Lawrentschuk, N., O’Brien, J., Buteau, J.P., Roberts, M., Francis, R.J., Tang, C., Vela, I., Thomas, P., Rutherford, N., Martin, J., Frydenberg, M., Shakher, R., Wong, L-M., Taubman, K., Lee, S.T., Hsiao, E., Nottage, M., Kirkwood, I., Iravani, A., Williams, S. and Hofman, M.S. (2023). Baseline PSMA PET-CT is prognostic for treatment failure in men with intermediate-to-high risk prostate cancer: 54 months follow-up of the proPSMA randomised trial. EAU23 - 38th Annual EAU Congress, Milan, Italy, 10-13 March 2023. Amsterdam, Netherlands: Elsevier. doi: 10.1016/s0302-2838(23)01275-7 |
|
2022 Conference Publication Genetic testing in prostate cancer: a scoping literature reviewEdmunds, Kim, Arora, Shiksha, Roberts, Matthew, Fairbairn, David, Scuffham, Paul, Smith, David, Chambers, Suzanne, Horvath, Lisa and Tuffaha, Haitham (2022). Genetic testing in prostate cancer: a scoping literature review. COSA's 49th Annual Scientific Meeting Equitable cancer care for all: Gender, identity, culture, geography, and disease should not matter, Online, 2–4 November 2022. Chichester, West Sussex United Kingdom: Wiley-Blackwell. |
|
2022 Conference Publication Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) compared to computed tomography (CT) for advanced renal cell carcinoma (RCC)Pathmanathan, Shivanshan, Tariq, Arsalan, Gan, Chun Loo, Pearce, Adam, Rhee, Handoo, Kyle, Samuel, Raveenthiran, Sheliyan, Wong, David, McBean, Rhiannon, Marsh, Philip, Goodman, Steven, Dhiantravan, Nattakorn, Esler, Rachel, Dunglison, Nigel, Navaratnam, Anojan, Yaxley, John, Thomas, Paul, Pattison, David A., Goh, Jeffrey C. and Roberts, Matthew (2022). Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) compared to computed tomography (CT) for advanced renal cell carcinoma (RCC). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, 3-7 June 2022. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2022.40.16_suppl.4540 |
|
2020 Conference Publication Comparing hybrid PSMA PET MRI and prostate biopsy histopathology in presumed localised prostate cancerMehawed, Georges, Tariq, Arsalan, Saadat, Paria, Joshi, Andre, Roberts, Matthew, Perera, Marlon, Rhee, Handoo, Gustafson, Sonja, Miles, Kenneth and Vela, Ian (2020). Comparing hybrid PSMA PET MRI and prostate biopsy histopathology in presumed localised prostate cancer. 18th Urological Association of Asia (UAA) Congress, Seoul, Korea, 15–17 October 2020. Richmond, VIC Australia: John Wiley & Sons. |
